Trial site
RKH Klinken Ludwigsburg-Bietigheim gGmbH
Ludwigsburg, 71640, GermanyNot linked to an institution yet
- 15running trials
- 6closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 24 trials
- Phase 41 trial
- Status
- Recruiting11 trials
- Completed6 trials
- Active, not recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- AstraZeneca3 trials
- Merck Sharp & Dohme LLC3 trials
- Amgen Inc.2 trials
- Dominik Paul Modest2 trials
- AGO Study Group1 trial
- and 10 more
Running trials
Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial
2024-516544-26-00· Phase 2· Universitaetsklinikum Heidelberg AöR· Source
Not yet recruiting
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477· Phase 3· Dominik Paul Modest· Source
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· Phase 3· AstraZeneca· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
NCT05551299· Phase 4· University of Leipzig· Source
Active, not recruiting
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· Phase 3· AstraZeneca· Source
Recruiting
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082· Phase 3· AGO Study Group· Source
Recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
NCT05008809· Phase 3· Dominik Paul Modest· Source
Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05255653· Phase 3· Leiden University Medical Center· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04447352· Phase 3· Krankenhaus Nordwest· Source
Active, not recruiting
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879· Phase 3· Bristol-Myers Squibb· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error